NCT03316573 2026-02-10Pembrolizumab in Neoplasms or LymphomasDana-Farber Cancer InstitutePhase 2 Suspended18 enrolled 16 charts
NCT04541108 2024-04-18Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesPresage BiosciencesPhase EARLY_PHASE1 Recruiting15 enrolled